Zangerle John Adam Form 4 March 28, 2019

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB APPROVAL

OMB 3235-0287 Number:

January 31, Expires: 2005

Estimated average burden hours per response... 0.5

if no longer subject to Section 16. Form 4 or Form 5

obligations

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

value

(Print or Type Responses)

1. Name and A Zangerle Jol	ddress of Reporting hn Adam	Symbol	2. Issuer Name and Ticker or Trading Symbol STERIS plc [STE]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O RUTHI STEPHENS WAY, CHA	ERFORD HOUS	(Month/l	of Earliest Tr Day/Year) 2019	ansaction			DirectorX Officer (give below)	10%	Owner er (specify	
	(Street) DE21 6LY	Filed(Mo	endment, Da onth/Day/Year)			Person	One Reporting Pe More than One Re	erson	
(City) 1.Title of Security (Instr. 3)	(State) 2. Transaction Dat (Month/Day/Year)	e 2A. Deemed	3. Transaction Code	4. Securition(A) or Dis (D) (Instr. 3, 4	ies Ac sposed	quired of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	of, or Beneficial 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Ordinary Shares, 10 pence par	03/28/2019		D	30,796 (1)	D	<u>(2)</u>	0	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Zangerle John Adam - Form 4

$\label{thm:convergence} \begin{tabular}{ll} Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned \\ (e.g., puts, calls, warrants, options, convertible securities) \end{tabular}$

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactionDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 45.34	03/28/2019		D	3,000	(3)	05/31/2023	Ordinary Shares	3,000
Employee Stock Option (right to buy)	\$ 53.52	03/28/2019		D	12,252	<u>(4)</u>	05/30/2024	Ordinary Shares	12,252
Employee Stock Option (right to buy)	\$ 67.98	03/28/2019		D	8,000	<u>(5)</u>	08/10/2025	Ordinary Shares	8,000
Employee Stock Option (right to buy)	\$ 69.72	03/28/2019		D	15,000	<u>(6)</u>	06/01/2026	Ordinary Shares	15,000
Employee Stock Option (right to buy)	\$ 77.07	03/28/2019		D	14,000	<u>(7)</u>	05/30/2027	Ordinary Shares	14,000
Employee Stock Option (right to buy)	\$ 114.22	03/28/2019		D	21,536	(8)	05/31/2028	Ordinary Shares	21,536

Reporting Owners

Reporting Owner Name / Address

Relationships

Edgar Filing: Zangerle John Adam - Form 4

Director 10% Owner Officer Other

Zangerle John Adam C/O RUTHERFORD HOUSE, STEPHENSONS WAY CHADDESDEN DERBY, X0 DE21 6LY

Sr. VP, Gen Counsel, and

Sec.

Signatures

/s/ Ronald E. Snyder, Authorized Representative under Power of Attorney

03/28/2019

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 19,136 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 3,000 on May 28, 2019; 4,000 on October 1, 2019; 2,500 on June 1, 2020; 6,000 on June 1, 2021 and 3,636 on May 31, 2022.

Represents ordinary shares of STERIS plc, a public limited company organized under the laws of England and Wales ("Old STERIS"), cancelled pursuant to a court-approved scheme of arrangement under English law (the "Scheme"). In connection with the Scheme, the reporting person received ordinary shares of STERIS plc, a public limited company organized under the laws of Ireland ("STERIS"), in

- an amount equal to the number of the reporting person's cancelled Old STERIS shares. The reporting person's STERIS shares will be subject to terms and conditions, including restrictions, substantially identical to those that were applicable to the Old STERIS shares. Following the completion of the Scheme, STERIS became the ultimate holding company of Old STERIS.
 - This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 3,000 ordinary shares of STERIS for \$45.34 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option.
- (3) This option was initially granted as an option to purchase 6,000 ordinary shares. On January 25, 2019, the reporting person exercised this option for 3,000 ordinary shares pursuant to a Rule 10b5-1 Stock Trading Plan, entered into by the reporting person on November 9, 2018.
- This option is fully vested. This option was assumed by STERIS under the Scheme and converted to an option to purchase 12,252

 (4) ordinary shares of STERIS for \$53.52 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option.
- This option will become exercisable as follows: 2,000 on May 28, 2016; 2,000 on May 28, 2017; 2,000 on May 28, 2018 and 2,000 on May 28, 2019. This option was assumed by STERIS under the Scheme and converted to an option to purchase 8,000 ordinary shares of STERIS for \$67.98 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option.
- This option becomes exercisable as follows: 3,750 on June 1, 2017; 3,750 on June 1, 2018; 3,750 on June 3, 2019 and 3,750 on June 1, 2020. This option was assumed by STERIS under the Scheme and converted to an option to purchase 15,000 ordinary shares of STERIS for \$69.72 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option.
- This option becomes exercisable as follows: 3,500 on May 30, 2018; 3,500 on May 30, 2019; 3,500 on June 1, 2020 and 3,500 on June 1, 2021. This option was assumed by STERIS under the Scheme and converted to an option to purchase 14,000 ordinary shares of STERIS for \$77.07 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option.
- This option becomes exercisable as follows: 5,384 on May 31, 2019; 5,384 on June 1, 2020; 5,384 on June 1, 2021 and 5,384 on May 31, (8) 2022. This option was assumed by STERIS under the Scheme and converted to an option to purchase 21,536 ordinary shares of STERIS for \$114.22 per share, subject to the same terms and conditions that were applicable to the original Old STERIS option.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3